Gyre Therapeutics presents poster on hydronidone at AASLD Meeting

Gyre Therapeutics announced the presentation of a poster at the American Association for the Study of Liver Diseases’ Annual Liver Meeting, November 10-14, 2023, in Boston, Massachusetts. Gyre‘s lead asset, Hydronidone, is currently being investigated for the treatment of Metabolic Dysfunction Associated Steatohepatitis-associated liver fibrosis in the United States. Gyre’s poster presented the potential antifibrotic effects of Hydronidone and its expected mode of action in mouse hepatic fibrosis models. Key highlights from the poster presentation are below: Hydronidone significantly improved liver damage in carbon tetrachloride and 3,5-diethoxycarbonyl-1,4-dihydropyridine mouse hepatic fibrosis models and reduced the accumulation of collagen; Hydronidone inhibited the activation of hepatic stellate cells via Smad7-mediated TGF- degradation and decreased the expression of fibrosis genes in hepatic stellate cells; In a ubiquitin-proteasome dependent pathway, Hydronidone promoted the Caveolin-1 mediated TGFbetaRI degradation via Smad7; Specific knockdown of Smad7 in vivo blocked the antifibrosis effect of Hydronidone.